DOCSLIB.ORG

Comparative Study of Efficacy of Topical Dexamethasone 0.1% with Difluprednate 0.05% in Post-Operative Small Incision Cataract Surgery

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Comparative Study of Efficacy of Topical Dexamethasone 0.1% with Difluprednate 0.05% in Post-Operative Small Incision Cataract Surgery Original Research Article DOI: 10.18231/2395-1451.2018.0076 Comparative study of efficacy of topical dexamethasone 0.1% with difluprednate 0.05% in post-operative small incision cataract surgery Rajashree Reddy1, Ashwini Patil2,* 1Associate Professor, 2Post Graduate Student, Dept. of Ophthalmology, Mahadevappa Rampure Medical College, Kalaburagi, Karnataka, India *Corresponding Author: Email: [email protected] Abstract Introduction: Post-operative ocular inflammation is a common occurrence following cataract surgery. Corticosteroids have been used to treat ocular inflammation; however, they carry a risk of side effects, particularly an increase in intra ocular pressure (IOP). Previous studies have proved that difluprednate is more efficacious compared to dexamethasone. Hence this study was undertaken to compare the efficacy of difluprednate ophthalmic emulsion 0.05% and dexamethasone 0.1% in postoperative management after small incision cataract surgery. Materials and Methods: A total 200 patients were selected as per inclusion criteria and equally divided between difluprednate and dexamethasone groups. Dexamethasone 0.1% or difluprednate0.05% was prescribed post operatively following small incision cataract surgery. Patients were examined on post-operative day 1, 7, 15 and 30 for anterior segment by slit-lamp examination and side effects. IOP was measured in both the groups on day 30. Results: In our observation both drugs were efficient in the reduction of anterior chamber cells and flare with difluprednate being more rapid. Corneal edema was reduced equally by both the drugs at all observation periods. There was no clinically significant IOP elevation in both difluprednate and dexamethsone group. Difluprednate was found to be more effective in controlling pain compared to dexamethasone. Conclusion: As per present study both difluprednate ophthalmic emulsion 0.05% eye drops and dexamethasone 0.1% eye drops were equally effective in reducing post cataract surgery inflammation. Hence, difluprednate emulsion 0.05% can be used in post- operative management after cataract surgery; nonetheless, further clinical trials with long follow- up period are required. Keywords: Cataract surgery, Dexamethasone, Difluprednate, Dose uniformity, Ocular inflammation, Opthalmic emulsion. Introduction inflammation and high chance of maintenance of The major cause of the blindness across the globe is integrity of blood aqueous barrier. In 1950, with the cataract, and around 1 to 4% population of the world arrival of cortisone in the medical field, there was major suffers from blindess. Cataract surgery should be advancement in the management of inflammatory performed with equal emphasis on quality and quantity conditions.3 of surgery.1 Surgical techniques in all fields of In the immediate post-operative period, topical ophthalmology has evolved considerably over the years corticosteroids are employed to suppress the production from transition to clear corneal incisions by anterior of inflammatory mediators, providing local treatment segment surgeons to adoption of small-gauge minimally without any side effects. Corticisteriods prevent the invasive pars planavitrectomies by vitreo- retinal release of arachidonic acid from cell membrane specialists. Cataract surgery can cause ocular phospholipids there by inhibiting the genesis of inflammation and it could be due to surgical trauma itself prostaglandins and leukotrines contributing to the and due to various physical, chemical and biological disruption of the inflammatory cascade. These agents are agents introduced during the surgery. The host response continued until the anterior chamber (AC) reaction has to these injurious agents in the form of inflammation is a resolved and the blood- aqueous barrier has been re- complex interaction of immuno reactive cells, their established.4 Routinely topical corticosteroids are in use products and other chemical mediators of inflammation. for the reduction of inflammation after surgery but side More is known today about chemical mediators of effects of corticosteriods are; inhibition of wound inflammation; the prostaglandins, the kinins the healing, high risk of infections and in some patients complement system etc and their role in inflammation. It intraocular hypertension also seen.5 is becoming more apparent that prostaglandins help to 0.05% difluprednate got US food and drug mediate the response of eye to acute trauma. This administration (FDA) approval in June 2008 for post- response is marked by miosis, hyperemia of conjunctiva, operative management of inflammation and pain. This is disturbance of blood aqueous barrier and transient the first ophthalmic steroid approved by FDA since increase in intraocular pressure followed by 1973. A study conducted showed that difluprednate hypotension.2 In the last few years cataract surgery emulsion 0.05% safely decreased the inflammation operative techniques have been improved tremendously associated with cataract surgery with no serious adverse and it has become least traumatic. And due to this effects compared to placebo. Thus difluprednate in the improved cataract surgeries there is low chance of ocular Indian Journal of Clinical and Experimental Ophthalmology, July-September, 2018;4(3):339-346 339 Rajashree Reddy et al. Comparative study of efficacy of topical dexamethasone… past 35 years has proved to be high potent, safe, and Patients in Group B received dexamethasone eye drops effectively reduces the post-operative pain.6 8 times and Moxifloxacin eye drops 4 times in a day for The emulsion formulations of difluprednate can be the 1st week followed by tapering of dexamethasone till credited to its dose uniformity.7 6th week. Various studies have proved that difluprednate is On 1,7,15 and 30 days of post-operative period each more efficacious compared to dexamethasone. There are patient was examined for pain, watering or any other few studies about the comparison of efficacy of symptom which has been experienced by the patient. For difluprednate and dexamethasone. Hence this study was the assessment of inflammation slit lamp examination undertaken to compare the efficacy of difluprednate was carried out and Snellen’s chart was used to assess ophthalmic emulsion 0.05% and dexamethasone 0.1% in visual acuity. With maintenance of standard conditions postoperative management after small incision cataract slit lamp examination was carried out: room was surgery. illuminated with dim light, voltage of the lamp was high, 3x1 millimeter aperture for Anterior chamber Flare and Materials and Methods Cells (Hogan’s grading). 30 degrees was used as Total two hundred patients diagnosed with senile illumination angle and magnification of 16x. Visual cataracts reported to HKE Society’s Basaveshwara analogue scale (VAS) was used to determine ocular pain. General and Teaching Hospital, Kalaburagi have been Symptoms of watering and discomfort were recorded as selected for the research. The study period was from present or absent. December 2015 to June 2017. Before the start of the At each visit the following parameters were noted study informed consent of the patient was acquired and and the degree of parameters are graded as 0,1,2,3, etc permission from the institutional ethical committee was As per VAS scale pain is graded as 0-absent, 1- procured. mild, 2-moderate, 3-severe and 4-extreme. A total of two hundred patients with senile cataract Corneal edema grading; 0- none, 1- mild, 2 - were divided into two groups. moderate, 3 -severe Group A- 100 cases (Difluprednate ophthalmic emulsion Anterior chamber flare grading: 0- absent, 1- mild, 0.05% group) 2- moderate (iris and lense details seen), 3- severe (iris Group B- 100 cases (Dexamethasone phosphate and lense details seen). ophthalmic suspension 0.1% group) Anterior chamber cells grading: grade 0 -absent, Inclusion Criteria: Patients diagnosed with cataract grade 1- 5 to 10 cells, grade 2 -11 to 20 cells, grade 3- 20 aged more than 40yrs and undergoing small incision to 50 cells. cataract surgery with PC IOL implantation. (If 50 cells and hypopyon was graded as 4 than Exclusion Criteria: Below years old patients, patients Pupils were examined for any synechiae or any other on long term steroids or NSAIDS, Patients sensitive to abnormalities). The details of the fundus were also noted any of the study or procedural medicines, patients with especially in the macula for the presence of cystoid preoperative inflammation in either eye, patients with macular edema by direct ophthalmoscopy. H/O ocular trauma, previous intraocular surgery or wear After 1 month, intraocular pressure was measured of contact lens, patients developing intraoperative with the help of applanation Tonometer and best complications, patients not giving consent, and patients corrected visual acuity was got after doing refraction. All undergoing phacoemulsification the above details were recorded in the clinical proforma Methodology: Before surgical procedure the patients at each visit. were evaluated for following; history was evaluated, slit Statistical analysis was done using Chi-square test lamp examination of the patient was done, visual acuity with Yate’s correction and Wilcoxon Signed Ranks test. was assessed, Keratometry has been done, A-scan has Statistical analysis using descriptive statistics and been done, and routine pre-operative blood inferential statistics has been done for this study. The investigations was carried out and blood pressure was results were analysed by using SPSS version
Load more

Recommended publications
  • (CD-P-PH/PHO) Report Classification/Justifica
    COMMITTEE OF EXPERTS ON THE CLASSIFICATION OF MEDICINES AS REGARDS THEIR SUPPLY (CD-P-PH/PHO) Report classification/justification of medicines belonging to the ATC group D07A (Corticosteroids, Plain) Table of Contents Page INTRODUCTION 4 DISCLAIMER 6 GLOSSARY OF TERMS USED IN THIS DOCUMENT 7 ACTIVE SUBSTANCES Methylprednisolone (ATC: D07AA01) 8 Hydrocortisone (ATC: D07AA02) 9 Prednisolone (ATC: D07AA03) 11 Clobetasone (ATC: D07AB01) 13 Hydrocortisone butyrate (ATC: D07AB02) 16 Flumetasone (ATC: D07AB03) 18 Fluocortin (ATC: D07AB04) 21 Fluperolone (ATC: D07AB05) 22 Fluorometholone (ATC: D07AB06) 23 Fluprednidene (ATC: D07AB07) 24 Desonide (ATC: D07AB08) 25 Triamcinolone (ATC: D07AB09) 27 Alclometasone (ATC: D07AB10) 29 Hydrocortisone buteprate (ATC: D07AB11) 31 Dexamethasone (ATC: D07AB19) 32 Clocortolone (ATC: D07AB21) 34 Combinations of Corticosteroids (ATC: D07AB30) 35 Betamethasone (ATC: D07AC01) 36 Fluclorolone (ATC: D07AC02) 39 Desoximetasone (ATC: D07AC03) 40 Fluocinolone Acetonide (ATC: D07AC04) 43 Fluocortolone (ATC: D07AC05) 46 2 Diflucortolone (ATC: D07AC06) 47 Fludroxycortide (ATC: D07AC07) 50 Fluocinonide (ATC: D07AC08) 51 Budesonide (ATC: D07AC09) 54 Diflorasone (ATC: D07AC10) 55 Amcinonide (ATC: D07AC11) 56 Halometasone (ATC: D07AC12) 57 Mometasone (ATC: D07AC13) 58 Methylprednisolone Aceponate (ATC: D07AC14) 62 Beclometasone (ATC: D07AC15) 65 Hydrocortisone Aceponate (ATC: D07AC16) 68 Fluticasone (ATC: D07AC17) 69 Prednicarbate (ATC: D07AC18) 73 Difluprednate (ATC: D07AC19) 76 Ulobetasol (ATC: D07AC21) 77 Clobetasol (ATC: D07AD01) 78 Halcinonide (ATC: D07AD02) 81 LIST OF AUTHORS 82 3 INTRODUCTION The availability of medicines with or without a medical prescription has implications on patient safety, accessibility of medicines to patients and responsible management of healthcare expenditure. The decision on prescription status and related supply conditions is a core competency of national health authorities.
    [Show full text]
  • A Note on Medical Management of Uveitis Apurupa Nedunuri Department of Pharmacology, Osmania University, Hyderabad, India
    OPEN ACCESS Freely available online e Journal of Pharmacovigilance ISSN: 2329-6887 Mini Review A Note on Medical Management of Uveitis Apurupa Nedunuri Department of Pharmacology, Osmania University, Hyderabad, India ABSTRACT Uveitis is a moving illness to treat. Corticosteroids have been utilized in the treatment of uveitis for a long time. Immunosuppressives are acquiring force lately in the treatment of uveitis. In this article we present an outline of current treatment of uveitis and the significant discoveries and advances in medications and visual medication conveyance frameworks in the treatment of uveitis. Keywords: Corticosteroids; Immunosuppressives; Medical Management; Uveitis. INTRODUCTION prednisolone acetic acid derivation is multiple times less powerful on a molar premise than betamethasone or dexamethasone, the Uveitis is a potentially sight threatening disease. It may occur due entrance into the cornea of prednisolone acetic acid derivation is to an infection or may be due to an autoimmune etiology. Specific significantly more than betamethasone or dexamethasone. Dosing antimicrobial therapies with or without corticosteroids are used recurrence and the time span the medicine stays in contact with in cases of infectious uveitis. Several drugs are available for the visual surface additionally impacts adequacy. Suspensions have a management of non-infectious uveitis including corticosteroids, immunosuppressive agents, and more recently biologics. The more serious level of calming impact. treatment of uveitis is evolving
    [Show full text]
  • Api Product Portfolio
    API PRODUCT PORTFOLIO Farmabios is the global leader in manufacturing Steroids . 1-3 nonsterile and sterile steroids, with a focused Sterile Steroids . 3-4 portfolio of High Potent Substances (HPS) and High Potent Substances . 4 anticancer drugs. Cannabinoids . 4 Antineoplastics . 4 Developments . 4 PharmaZell offers a focused portfolio of small molecule APIs for the generic and originator Small Molecules . 5-6 pharmaceutical industry. Developments . 6 Active Ingredient Therapeutic Monograph Available Regulatory CAS Number Areas Grades Documentation Steroids Amcinonide Dermatologic USP Micronized EU DMF 51022-69-6 Beclomethasone EU DMF PH.EUR. Standard Dipropionate Respiratory US DMF USP Micronized 5534-09-8 CEP Beclomethasone Dipropionate PH.EUR. EU DMF Respiratory Micronized Monohydrate USP US DMF 77011-63-3 Betamethasone EU DMF PH.EUR. Dipropionate Dermatologic Micronized US DMF USP 5593-20-4 CEP EU DMF Betamethasone PH.EUR. US DMF Valerate Dermatologic Micronized USP JP DMF 2152-44-5 CEP EU DMF PH.EUR. US DMF Budesonide Respiratory USP Micronized CEP 51333-22-3 Gastro-Intestinal JP JP DMF CN DMF Chlormadinone EU DMF PH.EUR. Acetate Contraceptive Micronized JP DMF JP 302-22-7 CEP* EU DMF Clobetasol PH.EUR. US DMF Propionate Dermatologic Micronized USP JP DMF 25122-46-7 CEP Clobetasone Butyrate Dermatologic PH.EUR. Micronized EU DMF 25122-57-0 Clocortolone EU DMF Pivalate Dermatologic USP Micronized US DMF 34097-16-0 Cyproterone EU DMF Acetate Anti-Androgen PH.EUR. Micronized US DMF 427-51-0 CEP Delmadinone Anti-Androgen INTERNAL Acetate Micronized EU DMF (Veterinary) SPEC. 13698-49-2 EU DMF Desonide Dermatologic USP Micronized US DMF 638-94-8 CN DMF Desonide Sodium INTERNAL Ophthalmic Standard EU DMF Phosphate SPEC.
    [Show full text]
  • Ophthalmic Anti-Inflammatories Therapeutic Class Review (TCR)
    Ophthalmic Anti-Inflammatories Therapeutic Class Review (TCR) October 20, 2020 No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, digital scanning, or via any information storage or retrieval system without the express written consent of Magellan Rx Management. All requests for permission should be mailed to: Magellan Rx Management Attention: Legal Department 6950 Columbia Gateway Drive Columbia, Maryland 21046 The materials contained herein represent the opinions of the collective authors and editors and should not be construed to be the official representation of any professional organization or group, any state Pharmacy and Therapeutics committee, any state Medicaid Agency, or any other clinical committee. This material is not intended to be relied upon as medical advice for specific medical cases and nothing contained herein should be relied upon by any patient, medical professional or layperson seeking information about a specific course of treatment for a specific medical condition. All readers of this material are responsible for independently obtaining medical advice and guidance from their own physician and/or other medical professional in regard to the best course of treatment for their specific medical condition. This publication, inclusive of all forms contained herein, is intended to be educational in nature and is intended to be used for informational purposes only. Send comments and suggestions to [email protected]. October 2020 Proprietary Information. Restricted Access – Do not disseminate or copy without approval. © 2004-2020 Magellan Rx Management. All Rights Reserved. FDA-APPROVED INDICATIONS Drug Manufacturer Indication(s) Corticosteroids – Ophthalmic Topical dexamethasone (Maxidex®)1 Alcon/Novartis .
    [Show full text]
  • Durezol Treats Postoperative Inflammation and Pain This Powerful Corticosteroid Is an Effective New Option for Postsurgical Care
    THERAPEUTICS Durezol Treats Postoperative Inflammation and Pain This powerful corticosteroid is an effective new option for postsurgical care. BY MICHAEL KORENFELD, MD cular surgery has undergone an extraordi- nary evolution. Much of the science that we now take for granted—drugs, instruments, O technology, and procedures—was devel- oped only within the past few decades. As recently as 1973, ophthalmologists’ treatment options were far more limited than they are today. There were no micro- incisions, self-sealing wounds, or Nd:YAG lasers. IOLs were an exciting innovation, but phacoemulsification had yet to be invented. In terms of ocular drugs, pred- nisolone acetate had just been approved for the treat- ment of ocular inflammation. Figure 1. The difluprednate molecule. Today, cataract surgery with IOL implantation is one of the most common surgical procedures performed in the tion of critical proteins, and hinder the creation of fur- United States. Its impressively low rate of complications ther inflammatory mediators.1 also makes it one of the safest operations in this country. The most commonly prescribed ophthalmic cortico- Incisions have become incredibly small, thanks to the steroid is prednisolone acetate 1%, a strong steroid, formu- development of foldable IOLs and other technological lated as a suspension (data on file with Sirion Therapeutics, breakthroughs. Inc.). The standard recommended dosing for this drug is Pharmacological developments, however, have not q.i.d. for the treatment of inflammation. Loteprednol kept pace with the tremendous advances in ocular sur- etabonate, 0.5%, another commonly prescribed steroid, is gery. We physicians need a steroid that treats inflamma- also typically dosed q.i.d.
    [Show full text]
  • Drug Pipeline MONTHLY UPDATE
    Drug Pipeline MONTHLY UPDATE Critical updates in an ever changing environment December 2019 NEW DRUG INFORMATION ™ ● Xcopri (cenobamate): The U.S. Food and Drug Administration (FDA) approved SK Biopharmaceuticals’ Xcopri as an antiepileptic drug for treatment of partial-onset seizures in adults. The approval is based on results from two global, randomized, double-blind, placebo-controlled studies and a large, global, multi-center, open-label safety study that enrolled adults with uncontrolled partial-onset seizures, taking one to three concomitant anti-epileptic drug (AEDs). In these studies, Xcopri demonstrated significant reductions in seizure frequency compared to placebo.1 Drug reaction with eosinophilia and systemic symptoms (DRESS) has been reported with Xcopri use. It has not been established that the risk of DRESS is prevented by a slower titration; however, it should be initiated at 12.5 mg once daily and titrated every two weeks. Xcopri is expected to be available in the United States 2Q2020, after scheduling review by the DEA, which typically occurs within 90 days of FDA approval. Price pending. GENERIC DRUG INFORMATION ® + ● Jadenu (deferasirox): Multiple manufacturers have launched their generic version of Novartis’ Jadenu for treatment of chronic iron overload. Jadenu generated $474 million in U.S. annual sales in 2018. ® ● Apriso (mesalamine ER): Multiple manufactures have launched their generic version of Bausch Health’s Apriso for treatment of ulcerative colitis. Apriso generated $312 million in U.S. annual sales in 2018. ® ● Nubupent (pentamidine isethionate): Fresenius launched their generic version of Seton Pharmaceuticals Nebupent inhaled solution for treatment of complicated lung infections. Nubupent does not have any further regulatory exclusivities.
    [Show full text]
  • Contact Dermatitis to Medications and Skin Products
    Clinical Reviews in Allergy & Immunology (2019) 56:41–59 https://doi.org/10.1007/s12016-018-8705-0 Contact Dermatitis to Medications and Skin Products Henry L. Nguyen1 & James A. Yiannias2 Published online: 25 August 2018 # Springer Science+Business Media, LLC, part of Springer Nature 2018 Abstract Consumer products and topical medications today contain many allergens that can cause a reaction on the skin known as allergic contact dermatitis. This review looks at various allergens in these products and reports current allergic contact dermatitis incidence and trends in North America, Europe, and Asia. First, medication contact allergy to corticosteroids will be discussed along with its five structural classes (A, B, C, D1, D2) and their steroid test compounds (tixocortol-21-pivalate, triamcinolone acetonide, budesonide, clobetasol-17-propionate, hydrocortisone-17-butyrate). Cross-reactivities between the steroid classes will also be examined. Next, estrogen and testosterone transdermal therapeutic systems, local anesthetic (benzocaine, lidocaine, pramoxine, dyclonine) antihistamines (piperazine, ethanolamine, propylamine, phenothiazine, piperidine, and pyrrolidine), top- ical antibiotics (neomycin, spectinomycin, bacitracin, mupirocin), and sunscreen are evaluated for their potential to cause contact dermatitis and cross-reactivities. Finally, we examine the ingredients in the excipients of these products, such as the formaldehyde releasers (quaternium-15, 2-bromo-2-nitropropane-1,3 diol, diazolidinyl urea, imidazolidinyl urea, DMDM hydantoin), the non- formaldehyde releasers (isothiazolinones, parabens, methyldibromo glutaronitrile, iodopropynyl butylcarbamate, and thimero- sal), fragrance mixes, and Myroxylon pereirae (Balsam of Peru) for contact allergy incidence and prevalence. Furthermore, strategies, recommendations, and two online tools (SkinSAFE and the Contact Allergen Management Program) on how to avoid these allergens in commercial skin care products will be discussed at the end.
    [Show full text]
  • April 1, 2019
    BUREAU FOR MEDICAL SERVICES EFFECTIVE WEST VIRGINIA MEDICAID PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA 04/01/2019 This is not an all-inclusive list of available covered drugs and includes only Version 2019.2e managed categories. Refer to cover page for complete list of rules governing this PDL. Prior authorization for a non-preferred agent in any class will be given only if there has been a trial of the preferred brand/generic equivalent or preferred formulation of the active ingredient, at a therapeutic dose, that resulted in a partial response with a documented intolerance. Prior authorization of a non-preferred isomer, pro-drug, or metabolite will be considered with a trial of a preferred parent drug of the same chemical entity, at a therapeutic dose, that resulted in a partial response with documented intolerance or a previous trial and therapy failure, at a therapeutic dose, with a preferred drug of a different chemical entity indicated to treat the submitted diagnosis. (The required trial may be overridden when documented evidence is provided that the use of these preferred agent(s) would be medically contraindicated.) Unless otherwise specified, the listing of a particular brand or generic name includes all legend forms of that drug. OTC drugs are not covered unless specified. PA criteria for non-preferred agents apply in addition to general Drug Utilization Review policy that is in effect for the entire pharmacy program, including, but not limited to, appropriate dosing, duplication of therapy, etc. The use of pharmaceutical samples will not be considered when evaluating the members’ medical condition or prior prescription history for drugs that require prior authorization.
    [Show full text]
  • Prior Authorization PDL Implementation Schedule
    Prior Authorization PDL Implementation Schedule Effective Date: Item January 1, 2017 – Descriptive Therapeutic Class Drugs on PDL Drugs which Require PA Nbr Updated: March 1, 2018 1 ADD/ADHD Amphetamine Salt Combo Tablet ( Generic Adderall®) Amphetamine ODT (Adzenys® XR ODT) Stimulants and Related Agents Amphetamine Salt Combo ER (Adderall XR®) Amphetamine Suspension (Dyanavel XR®) Atomoxetine Capsule (Strattera®) Amphetamine Salt Combo ER (Generic; Authorized Generic for Adderall XR) Dexmethylphenidate (Generic; Authorized Generic of Focalin®) Amphetamine Sulfate Tablet (Evekeo®) Dexmethylphenidate ER (Focalin XR®) Armodafinil Tablet (Generic; Authorized Generic; Nuvigil®) Dextroamphetamine Solution (Procentra®) Clonidine ER Tablet (Generic; Kapvay®) Dextroamphetamine Sulfate Tablet (Generic) Dexmethylphenidate (Focalin®) Guanfacine ER Tablet (Generic) Dexmethylphenidate XR (Generic; Authorized Generic for Focalin XR) Lisdexamfetamine Capsule (Vyvanse®) Dextroamphetamine Sulfate Capsule ER (Generic; Dexedrine®Spansule) Methylphenidate IR (Generic) Dextroamphetamine IR Tablet (Zenzedi®) Methylphenidate ER Chew (Quillichew ER®) Dextroamphetamine Solution (Generic for Procentra®) Methylphenidate ER Capsule (Metadate CD®) Guanfacine ER Tablet (Intuniv®) Methylphenidate ER Tablet (Generic; Generic Concerta®; Methamphetamine (Generic; Desoxyn®) Authorized Generic Concerta®) Methylphenidate ER Susp (Quillivant XR®) Methylphenidate IR (Ritalin®) Modafinil Tablet (Generic) Methylphenidate Solution (Generic; Authorized Generic; Methylin®) Methylphenidate
    [Show full text]
  • Federal Bureau of Prisons Health Services National Formulary Part I
    Federal Bureau of Prisons Health Services National Formulary Part I Approved: Jeffery D. Allen, MD, MEDICAL DIRECTOR Page 1 of 46 Table of Contents Summary of Formulary Changes Winter 2019 Meeting ..................................................................................................................... 3 National BOP Formulary Mission / Procedural Statement ............................................................................................................................ 4 Definitions/Rules ............................................................................................................................................................................... 6 FDA Medication Guides and Side Effects Statement .......................................................................................................................... 7 Over The Counter Medications .......................................................................................................................................................... 7 Directly Observed Therapy (Formerly “Pill Line”) Only ....................................................................................................................... 7 Non-Substitutable Products ............................................................................................................................................................... 8 Look Alike/Sound Alike Medications .................................................................................................................................................
    [Show full text]
  • Uveitis Therapy: the Corticosteroid Options
    Drugs https://doi.org/10.1007/s40265-020-01314-y REVIEW ARTICLE Uveitis Therapy: The Corticosteroid Options Lianna M. Valdes1 · Lucia Sobrin1 © Springer Nature Switzerland AG 2020 Abstract Uveitis is characterized by intraocular infammation involving the uveal tract; its etiologies generally fall into two broad categories: autoimmune/infammatory or infectious. Corticosteroids are a powerful and important class of medications ubiquitous in the treatment of uveitis. They may be given systemically or locally, in the form of topical drops, periocular injection, intravitreal suspension, or intravitreal implant. This review describes each of the currently available corticosteroid treatment options for uveitis, including favorable and unfavorable characteristics of each as well as applicable clinical trials. The main advantage of corticosteroids as a whole is their ability to quickly and efectively control infammation early on in the course of uveitis. However, they can have serious side efects, whether localized to the eye (such as cataract and elevated intraocular pressure) or systemic (such as osteonecrosis and adrenal insufciency) and in the majority of cases of uveitis are not an appropriate option for long-term therapy. Key Points Clinical features of uveitis include keratic precipitates, ante- rior chamber cell and fare, anterior and posterior synechiae, Corticosteroids are an important mainstay in the treat- iris nodules, snowballs, snowbanks, vitreous haze and cells, ment of uveitis. choroidal lesions, and choroidal thickening. Uncontrolled uveitis can be complicated by cystoid macular edema, retinal Corticosteroids can be given systemically or locally, in vasculitis, optic nerve head edema, and subretinal fuid. A the form of topical drops, periocular injection, intravit- mainstay of treatment for uveitis and its sequelae is the use real suspension, or intravitreal implant; each option has of corticosteroids.
    [Show full text]
  • Therapeutic Drug Class
    EFFECTIVE Version Department of Vermont Health Access Updated: 06/05/20 Pharmacy Benefit Management Program /2016 Vermont Preferred Drug List and Drugs Requiring Prior Authorization (includes clinical criteria) The Commissioner for Office of Vermont Health Access shall establish a pharmacy best practices and cost control program designed to reduce the cost of providing prescription drugs, while maintaining high quality in prescription drug therapies. The program shall include: "A preferred list of covered prescription drugs that identifies preferred choices within therapeutic classes for particular diseases and conditions, including generic alternatives" From Act 127 passed in 2002 The following pages contain: • The therapeutic classes of drugs subject to the Preferred Drug List, the drugs within those categories and the criteria required for Prior Authorization (P.A.) of non-preferred drugs in those categories. • The therapeutic classes of drugs which have clinical criteria for Prior Authorization may or may not be subject to a preferred agent. • Within both categories there may be drugs or even drug classes that are subject to Quantity Limit Parameters. Therapeutic class criteria are listed alphabetically. Within each category the Preferred Drugs are noted in the left-hand columns. Representative non- preferred agents have been included and are listed in the right-hand column. Any drug not listed as preferred in any of the included categories requires Prior Authorization. Approval of non-preferred brand name products may require trial and failure of at least 2 different generic manufacturers. GHS/Change Healthcare Change Healthcare GHS/Change Healthcare Sr. Account Manager: PRESCRIBER Call Center: PHARMACY Call Center: Michael Ouellette, RPh PA Requests PA Requests Tel: 802-922-9614 Tel: 1-844-679-5363; Fax: 1-844-679-5366 Tel: 1-844-679-5362 Fax: Note: Fax requests are responded to within 24 hrs.
    [Show full text]